Welcome to our dedicated page for Akari Therapeutics Plc SEC filings (Ticker: AKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Akari Therapeutics plc (AKTX) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, including current reports, registration statements, and proxy materials related to its oncology ADC platform. These documents are a primary source for understanding how Akari describes its PH1 spliceosome-modulating payload, lead ADC candidate AKTX-101, and broader corporate strategy.
Through Forms 8-K, Akari reports material events such as equity financings, warrant issuances, note offerings and exchanges, manufacturing partnerships, and leadership changes. Recent 8-K filings detail registered direct offerings and concurrent private placements, the terms of Series E, Series F, and Series G warrants, exchanges of unsecured promissory notes into equity-linked securities, and the company’s plans to use net proceeds for research and development, working capital, and general corporate purposes. Other 8-Ks describe Nasdaq minimum bid price deficiency notices and the company’s responses.
Akari’s registration statements, including shelf registrations and resale S-1 filings, outline the structure of its American Depositary Shares, the number of ordinary shares underlying various warrant series, and risk factor discussions related to its status as a development-stage oncology company without approved products or product revenue. These filings also summarize the company’s focus on developing ADCs with novel payloads and the role of its ADC discovery platform.
Proxy statements (DEF 14A) provide detail on shareholder meetings, resolutions related to share sub-division, warrant exercisability, authority to allot shares, and adoption of new articles of association. They also describe voting procedures for ordinary shareholders and ADS holders.
On Stock Titan, Akari’s SEC filings are updated in near real time from EDGAR and paired with AI-powered summaries that highlight key terms, capital structure changes, and regulatory milestones. Users can quickly scan 10-K or 20-F style risk discussions (when available), 10-Q or 6-K interim updates, and Form 4 insider transaction reports, then drill into the full text for deeper analysis of how financing, governance, and listing matters intersect with the company’s PH1-based ADC development plans.
Akari Therapeutics plc (NASDAQ: AKTX) – Form 4 insider transaction
On 06/20/2025, President & Chief Executive Officer Abizer Gaslightwala, who also serves as a director of the company, purchased 10,000 American Depositary Shares (ADS) of Akari Therapeutics in an open-market transaction. The shares were acquired at a price of $1.20 per ADS, for an aggregate consideration of approximately $12,000.
Following the purchase, the reporting person’s direct holding increased to 271,428 ADS. Each ADS represents 2,000 ordinary shares of Akari Therapeutics with a par value of $0.0001 per ordinary share, as noted in the footnote to the filing.
No dispositions were reported, and the filing shows no derivative security transactions. The form was signed by Torsten Hombeck, acting as attorney-in-fact, on 06/24/2025.
This Form 4 therefore documents a single, straightforward insider purchase by the company’s most senior executive, with no accompanying sales or option exercises disclosed.
Insider Purchase Alert: Abizer Gaslightwala, President & CEO and Director of Akari Therapeutics, has acquired 15,000 American Depositary Shares (ADS) at a price of $1.20 per share on June 17, 2025. Each ADS represents 2,000 ordinary shares of the company.
Following this transaction, Gaslightwala now beneficially owns 261,428 ADSs directly. This insider purchase demonstrates a significant investment by the company's top executive, potentially signaling confidence in the company's future prospects.
- Transaction Type: Direct Purchase (Form 4)
- Total Investment Value: $18,000
- Transaction Date: June 17, 2025
- Filing Date: June 28, 2025
- Ownership Form: Direct